title: Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
abstract: BACKGROUND
  Bleomycin pulmonary toxicity (BPT) has been described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens.
  
  
  METHODS
  We reviewed the records of 164 consecutive HL patients.
  
  
  RESULTS
  BPT was observed in 24 of 164 patients (15%). Older age and history of concomitant lung disease were significantly associated with approximately threefold (odds ratio: 3.38; 95% CI: 1.25-9.13; p = 0.02) and sevenfold (odds ratio: 7.19; 95% CI: 2.64-19.54; p < 0.0001) increase in BPT risk, respectively. The actuarial 5-year progression-free and overall survival for BPT and non-BPT groups, were not significantly different.
  
  
  CONCLUSIONS
  In Saudi Arabian HL patients, the risk of BPT and its effect on survival outcome were comparable to that reported from developed countries.
authors.affiliation: Princess Noorah Oncology Center, King Abdulaziz Medical City, PO BOX 9515, Jeddah 21423, Kingdom of Saudi Arabia.
authors.forename: Wafa'a A
authors.initials: WA
authors.lastname: Al-Jizani
authors.affiliation: Princess Noorah Oncology Center, King Abdulaziz Medical City, PO BOX 9515, Jeddah 21423, Kingdom of Saudi Arabia.
authors.forename: Mubarak M
authors.initials: MM
authors.lastname: Al-Mansour
authors.affiliation: Princess Noorah Oncology Center, King Abdulaziz Medical City, PO BOX 9515, Jeddah 21423, Kingdom of Saudi Arabia.
authors.forename: Turki M
authors.initials: TM
authors.lastname: Al-Fayea
authors.affiliation: Princess Noorah Oncology Center, King Abdulaziz Medical City, PO BOX 9515, Jeddah 21423, Kingdom of Saudi Arabia.
authors.forename: Ruaa U
authors.initials: RU
authors.lastname: Shafi
authors.affiliation: Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Kingdom of Saudi Arabia.
authors.forename: Ghieth A
authors.initials: GA
authors.lastname: Kazkaz
authors.affiliation: Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Kingdom of Saudi Arabia.
authors.forename: Ali M
authors.initials: AM
authors.lastname: Bayer
authors.affiliation: Princess Noorah Oncology Center, King Abdulaziz Medical City, PO BOX 9515, Jeddah 21423, Kingdom of Saudi Arabia.
authors.forename: Meteb E
authors.initials: ME
authors.lastname: Al-Foheidi
authors.affiliation: Oncology Center of Excellence, International Medical Center, PO Box 2172, Jeddah 21451, Kingdom of Saudi Arabia.
authors.forename: Ezzeldin M
authors.initials: EM
authors.lastname: Ibrahim
mesh_terms: D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000503:physiopathology; D008171:Lung Diseases / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012529:Saudi Arabia; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin
keywords: Hodgkin's lymphoma; bleomycin; prognosis; pulmonary; toxicity